clinicaltrials.gov/study/NCT066...
clinicaltrials.gov/study/NCT066...
SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)
WATCH NOW:
youtu.be/i_YTcIQ4YQk?...
@danfuster.bsky.social
@gunnarheine.bsky.social
@marcussaemann.bsky.social
SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)
WATCH NOW:
youtu.be/i_YTcIQ4YQk?...
@danfuster.bsky.social
@gunnarheine.bsky.social
@marcussaemann.bsky.social
rdcu.be/efxE2
rdcu.be/efxE2
In a post hoc analysis of NOSTONE (where CT scans were done in all & repurposed for calculating bone density) HCTZ doesn’t increase it vs placebo
journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social
In a post hoc analysis of NOSTONE (where CT scans were done in all & repurposed for calculating bone density) HCTZ doesn’t increase it vs placebo
journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social
journals.lww.com/cjasn/abstra...
HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years!
journals.lww.com/cjasn/abstra...
HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years!
journals.lww.com/cjasn/abstra...
journals.lww.com/cjasn/abstra...
Wonderful collaboration with colleagues @unibern @inselgruppe and DCR Bern.
www.nature.com/articles/s41...
Empagliflozin substantially reduced urinary supersaturations in non-diabetic patients with kidney stones.
Wonderful collaboration with colleagues @unibern @inselgruppe and DCR Bern.
www.nature.com/articles/s41...
Empagliflozin substantially reduced urinary supersaturations in non-diabetic patients with kidney stones.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
You can speculate about the additional effects of citrate or a different type or dose of diuretic, … 1/2
You can speculate about the additional effects of citrate or a different type or dose of diuretic, … 1/2
"Whether there will be a definitive, adequately powered trial of this inexpensive, fairly safe intervention in CKD is up to funding
agencies to decide"
Cardiology is doing large outcome trials with colchicine - why can we not do this with alkali ?
"Whether there will be a definitive, adequately powered trial of this inexpensive, fairly safe intervention in CKD is up to funding
agencies to decide"
Cardiology is doing large outcome trials with colchicine - why can we not do this with alkali ?